Current Report Filing (8-k)
June 09 2023 - 4:31PM
Edgar (US Regulatory)
0001321834
false
0001321834
2023-06-09
2023-06-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 9, 2023
MyMD
Pharmaceuticals, Inc.
(Exact
name of Registrant as specified in its charter)
New
Jersey |
|
001-36268 |
|
22-2983783 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
No.) |
|
(IRS
Employer
Identification
No.) |
MyMD
Pharmaceuticals, Inc.
855
N. Wolfe Street, Suite 601
Baltimore,
MD 21205
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: (856) 848-8698
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
Registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
stock, no par value per share |
|
MYMD |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.08 Shareholder Director Nominations.
On
June 9, 2023, the Board of Directors of MyMD Pharmaceuticals, Inc. (the “Company”) determined that the Company’s 2023
Annual Meeting of Stockholders (the “Annual Meeting”) will be held virtually by means of remote communication on July 31,
2023. Stockholders of record of the Company’s common stock at the close of business on June 21, 2023 will be entitled to notice
of, and to vote at, the Annual Meeting.
Due
to the fact that the date of the Annual Meeting has been changed by more than 30 days from the anniversary date of the 2022 Annual Meeting
of Stockholders, the Company is providing the due date for submission of any qualified stockholder proposal or qualified stockholder
nominations. Stockholders of the Company who wish to have a proposal considered for inclusion in the Company’s proxy materials
for the Annual Meeting pursuant to Rule 14a-8 under the Securities Exchange Act of 1934 (the “Exchange Act”), must ensure
that such proposal is received by the Company’s Secretary at its corporate office at 855 N. Wolfe Street, Suite 601, Baltimore,
MD 21205, on or before the close of business on June 19, 2023, which the Company has determined to be a reasonable time before it expects
to begin in print and send its proxy materials in accordance with Rule 14a-5(f) and Rule 14a-8(e) under the Exchange Act. Any such proposal
must also meet the requirements set forth in the rules and regulations of the Securities and Exchange Commission in order to be eligible
for inclusion in the proxy materials for the Annual Meeting.
In
addition, in accordance with the requirements contained in the Company’s Bylaws, stockholders of the Company who wish to bring
business before the Annual Meeting outside of Rule 14a-8 of the Exchange Act or to nominate a person for election as a director must
ensure that written notice of such proposal (including all information specified in the Company’s Bylaws) is received by the Company’s
Secretary at the address specified above no later than the close of business on June 19, 2023. Any such proposal must meet the requirements
set forth in the Company’s Bylaws in order to be brought before the Annual Meeting.
In
addition, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other
than our nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act by June 19, 2023.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
MYMD
PHARMACEUTICALS, INC. |
|
|
|
Date:
June 9, 2023 |
By:
|
/s/
Chris Chapman |
|
|
Chris
Chapman, M.D. |
|
|
President |
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jul 2024 to Aug 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Aug 2023 to Aug 2024